Pàgina inicial > Resultats de la cerca: Simpson, David
  Consells de cerca
Cerca simple
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Dipòsit Digital de Documents de la UAB 4 registres trobats  La cerca s'ha fet en 0.01 segons. 
1.
9 p, 996.2 KB Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : Extended phase 3 results from RESONATE-2 / Barr, Paul M. (University of Rochester) ; Robak, Tadeusz (Medical University of Lodz) ; Owen, Carolyn (Tom Baker Cancer Centre) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Bairey, Osnat (Sackler Faculty of Medicine. Tel Aviv University) ; Bartlett, Nancy L. (Washington University School of Medicine) ; Burger, Jan A. (University of Texas MD Anderson Cancer Center) ; Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Coutre, Steven E (Stanford University School of Medicine) ; Devereux, Stephen (Kings College Hospital) ; Grosicki, Sebastian (School of Public Health. Silesian Medical University) ; McCarthy, Helen (Royal Bournemouth Hospital) ; Li, Jianyong (Jiangsu Province Hospital) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Zhou, Cathy (Pharmacyclics. LLC an AbbVie Company) ; Styles, Lori (Pharmacyclics. LLC an AbbVie Company) ; James, Danelle (Pharmacyclics. LLC an AbbVie Company) ; Kipps, Thomas J (University of California,San Diego. Moores Cancer Center) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ; Universitat Autònoma de Barcelona
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic Rleukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. [...]
2018 - 10.3324/haematol.2018.192328
Haematologica, Vol. 103 Núm. 9 (31 2018) , p. 1502-1510  
Registre complet - Creative Commons
2.
9 p, 1.3 MB Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia : A cross-trial comparison of phase 3 studies / Robak, Tadeusz (Medical University of Lodz) ; Burger, Jan A. (The University of Texas MD Anderson Cancer Center) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Barr, Paul M. (University of Rochester Cancer Center) ; Owen, Carolyn (University of Calgary) ; Bairey, Osnat (Tel Aviv University) ; Hillmen, Peter (St. James's Institute of Oncology) ; Simpson, David (North Shore Hospital) ; Grosicki, Sebastian (Silesian Medical University) ; Devereux, Stephen (King's College Hospital NHS Foundation Trust) ; McCarthy, Helen (Royal Bournemouth Hospital) ; Coutre, Steven E (Stanford University School of Medicine) ; Quach, Hang (St. Vincent's Hospital) ; Gaidano, Gianluca (Amedeo Avogadro University of Eastern Piedmont) ; Maslyak, Zvenyslava (Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine) ; Stevens, Don A. (Norton Cancer Institute) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Gill, Devinder S. (Princess Alexandra Hospital) ; Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ; Gribben, John G. (Queen Mary University of London) ; Mokatrin, Ahmad (Pharmacyclics LLC. an AbbVie Company) ; Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ; Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Kipps, Thomas J (University of California San Diego) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ; Universitat Autònoma de Barcelona
Chemoimmunotherapy (CIT) and targeted therapy with single-agent ibrutinib are both recommended first-line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. [...]
2018 - 10.1002/ajh.25259
American Journal of Hematology, Vol. 93 Núm. 11 (november 2018) , p. 1402-1410  
Registre complet - Creative Commons
3.
12 p, 1.8 MB Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study / Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ; Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ; Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ; Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ; Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ; Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ; Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ; Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ; Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ; McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ; Kipps, Thomas J. (UCSD Moores Cancer Center) ; Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798  
Registre complet - Creative Commons
4.
5 p, 238.6 KB The development and characterisation of a bacterial artificial chromosome library for Fragaria vesca / Bonet Gigante, Julio (Centre de Recerca en Agrigenòmica) ; López Girona, Elena (East Malling Research) ; Sargent, Daniel J. (East Malling Research) ; Muñoz Torres, Monica C. (Clemson University. Department of Genetics and Biochemistry) ; Monfort, Amparo (Centre de Recerca en Agrigenòmica) ; Abbott, Albert G. (Clemson University. Department of Genetics and Biochemistry) ; Arús i Gorina, Pere (Centre de Recerca en Agrigenòmica) ; Simpson, David W. (East Malling Research) ; Davik, Jahn (Bioforsk Midt-Norge)
BACKGROUND: the cultivated strawberry Fragaria xananassa is one of the most economically-important soft-fruit species. Few structural genomic resources have been reported for Fragaria and there exists an urgent need for the development of physical mapping resources for the genus. [...]
2009 - 10.1186/1756-0500-2-188
BMC research notes, Vol. 2 (Set. 2009) , art. 188  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem